Drug Discovery@nature.com 7 October 2011

Advertisement RNA-Seq just went from complicated to compatible. EA will provide your data in a format you are used to -- 100% microarray compatible format. Now you can have your data and use it too! Expresssion Analysis will help you detect 2x more differentially expressed transcripts, novel isoforms and SNVs and can achieve >97% alignment to your reference genome. 919-405-2248 TABLE OF CONTENTS 7 October 2011 News Analysis Research Highlights Research & Reviews Careers Advertisement Discover Relevant Variance Don't risk valuable time and resources using tools that fail to generate biologically relevant data for pharmacogenetic research. Isolate the data you need, at the cost you want, with Sequenom's iPLEX® ADME PGx panel. Change the course of your research today with the iPLEX ADME PGX Find out more here Nature Reviews Drug Discovery is on Twitter Advertisement The Renin-Angiotensin System: Today and Tomorrow in Research and Clinical Practice December 11-13, 2011 • Miami, FL, USA The conference will bring together leaders in the field to present a comprehensive, authoritative update on renin-angiotensin system (RAS) inhibition for improved clinical outcomes and to explore future options for targeting the RAS and its related pathways. www.nature.com/natureconferences/ras11?WT.mc_id=NC1108TK010   News Top Companies hope for kinase inhibitor JAKpot doi:10.1038/nrd3571 Drugs that block Janus kinases are showing promise in diseases ranging from myelofibrosis to rheumatoid arthritis, but with the leading agent in line for approval questions remain about their optimal selectivity. Full Text Gene therapies advance towards finish line doi:10.1038/nrd3572 Over a decade since gene therapy development came to a near standstill with the death of a clinical trial participant, the field is overcoming issues of immunogenicity, carcinogenicity, manufacturing and small patient populations. Full Text Draft guidelines for nanomedicine unveiled doi:10.1038/news.2011.562 With hundreds of nanoproducts currently being tested in humans, recommendations aim to safeguard trial participants. Full Text Translational research: 4 ways to fix the clinical trial doi:10.1038/477526a Clinical trials are crumbling under modern economic and scientific pressures. Nature looks at ways they might be saved. Full Text Analysis Top Eradicating leukemia stem cells doi:10.1038/scibx.2011.1056 Inhibiting the oncoprotein BCL6 improves the efficacy of tyrosine kinase inhibitors in mouse models of two types of leukemia, suggesting that BCL6 inhibitors already being developed could potentially lead to shorter tyrosine kinase inhibitor treatment. Full Text Ezogabine (retigabine) doi:10.1038/nrd3561 Ezogabine, a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine. Full Text Antibacterial R&D incentives doi:10.1038/nrd3560 This article outlines the objectives of incentives for antibacterial R&D and compares the ability of various incentive policies to address the long-term challenge of antibacterial resistance. Full Text Research Highlights Top Antivirals: New clues for flu vaccine design doi:10.1038/nrd3567 Human monoclonal antibodies exhibiting broad neutralizing activity against type A influenza viruses have been identified. Full Text Synthetic biology: Licensing bacteria to kill doi:10.1038/nrmicro2660 Reports on the design and testing of an engineered Escherichia coli strain that specifically targets Pseudomonas aeruginosa. Full Text Immunotherapy: Leukadherins get a grip on inflammation doi:10.1038/nri3079 New drugs promoting integrin activation prevent inflammatory cells from being recruited to inflamed tissues. Full Text Research & Reviews Top The influence of the 'organizational factor' on compound quality in drug discovery doi:10.1038/nrd3552 The results of an in-depth comparison of patented compounds from different companies acting on the same targets indicates the continued production of compounds with suboptimal physiochemical profiles. Full Text Development of subtype-selective oestrogen receptor-based therapeutics doi:10.1038/nrd3551 This article outlines the roles of oestrogen receptor α and oestrogen receptor β in various animal disease models, and details how agonists that selectively target either receptor subtype might provide a more efficacious therapy than targeting both for certain diseases. Full Text The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension doi:10.1038/nm.2497 This article describes how thiazide diuretics could be used to prevent hypertension mediated by activation of the renal sodium chloride cotransporter that is associated with the use of calcineurin inhibitor immunosuppressants. Full Text Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia doi:10.1038/nature10509 In this study, a novel small molecule inhibitor of the BET family has been shown to displace BET proteins from chromatin to induce early cell cycle arrest and apoptosis in MLL-fusion leukaemic cell lines and to provide survival benefit in two mouse models of leukaemia. Full Text Drug Discovery JOBS of the week Groupleader Structural Biology Steyaert Lab, VUB-VIB Brussels, BE Assistant Professor (tenured-track) University of Tennessee Health Science Center Memphis, US BIOINFORMATICS Software Developer Genoscope (CEA) Évry, FR Computational Biology / Bioinformatics Postdoctoral Positions Emory University Atlanta, US Scientist, Vascular and Lymph System Biology Genentech San Francisco, US More Science jobs from Drug Discovery EVENT 6th Annual Conference on Drug Discovery and Clinical Development: Convergence of Science, Medicine, and Market Access Strategies to Benefit Patients 15.-18.10.11 Mumbai, India More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.